Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis
- 116 Downloads
This study was done to determine whether intravenous methylprednisolone therapy given concomitantly with low-dose daily, oral prednisone would be as effective as highdose daily prednisone in the treatment of patients with active systemic lupus erythematosus (SLE) nephritis.
Thirteen patients with active SLE nephritis were started on 2 mg/kg prednisone per day, considered the high prednisone phase. Therapy was continued until remission was achieved. Prednisone administration was then tapered to less than 0.5 but more than 0.2 mg/kg per day. On later relapse, these patients received three doses of methylprednisolone (20 mg/kg per dose) on alternate days and continued on the same daily dose of prednisone (<0.5 >0.2 mg/kg per day) prior to pulse therapy; this was the methylprednisolone phase. The 13 patients were studied in both phases, serving as their own controls.
After 1 month of therapy, no significant differences were observed between treatment phases as to improvement in clinical and laboratory findings. A significant increase in the serum concentration of C3 and C4 was seen both in the highdose prednisone and methylprednisolone phases, while the serum concentration of anti-ds DNA antibody significantly decreased.
Methylprednisolone therapy seems as effective as highdose prednisone in patients with relapse of SLE nephritis. Because side effects are minimal, methylprednisolone administration may be tried as the therapy of choice for these patients.
Key wordsLupus erythematosus Glomerulonephritis Methylprednisolone
systemic lupus erythematosus
Unable to display preview. Download preview PDF.
- 1.Albert DA, Hadler NM, Ropes MW (1979) Does corticosteroid therapy effect the survival of patients with systemic lupus erythematosus. Arthritis Rheum 22:945–953Google Scholar
- 2.Appel AE, Sablay LB, Golden RA, Barland P, Grayzel AI, Bank N (1978) The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis: a two-year prospective study. Am J Med 64:274–283Google Scholar
- 3.Baldwin DS (1983) Lupus nephritis. In: Massry SG, Glassock RJ (eds) Textbook of Nephrology. Williams and Wilkins, Baltimore, pp 679–694Google Scholar
- 4.Barron KS, Person DA, Brewer EJ Jr, Beale MG, Robson AM (1982) Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr 101:137–141Google Scholar
- 5.Cathcart ES, Scheinberg MA, Idelson BA, Couser WG (1976) Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet 1:163–166Google Scholar
- 6.Cohen AS, Reynolds WE, Franklin EC, Kulka JP, Ropes MW, Shulman LE, Wallace SL (1971) Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 21:643–648Google Scholar
- 7.Dornfeld L, Bluestone R (1976) Therapy of diffuse lupus glomerulonephritis. Arthritis Rheum 19:833–834Google Scholar
- 8.Fish AJ, Vernier RL, Michael AF (1978) Systemic lupus erythematosus. In: Edelman CM (ed) Pediatric kidney disease Little, Brown and Company, Boston, pp 745–767Google Scholar
- 9.Garin EH, Donnelly WH, Shulman ST, Fernandez R, Finton C, Willimas RL, Richard GA (1979) The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis. Clin Nephrol 12:148–155Google Scholar
- 10.Gladman DD, Vrowitz MDM, Keystone EC (1979) Serologically active clinically quiescent SLE: a discordance between clinical and serological features. Am J Med 11:210–216Google Scholar
- 11.Hill GS, Hinglais N, Tron F, Bach JF (1978) Systemic lupus erythematosus. Morphologic correlations and clinical data at the time of biopsy. Am J Med 64:61–79Google Scholar
- 12.Isenberg DA, Morrow WJW, Snaith ML (1982) Methylprednisolone pulse therapy in systemic lupus erythematosus. Ann Rheum Dis 41:345–351Google Scholar
- 13.Jarrett MP, Sablay LB, Walter L, Barland P, Graysel AI (1981) The effect of continuous normalizations of serum hemolytic complement in the course of lupus nephritis. Am J Med 70:1067–1072Google Scholar
- 14.Kaplan D (1977) Treatment of systemic lupus erythematosus. Arthritis Rheum 20:S175–179Google Scholar
- 15.Kimberly RP, Lockshin MD, Sherman RL, McDougal JS, Inman RD, Christian CL (1981) High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 70:817–824Google Scholar
- 16.Lightfoot RS Jr, Hughes GRV (1976) Significance of peristing serologic abnormalities in SLE. Arthritis Rheum 19:837–843Google Scholar
- 17.Lloyd W, Schur PH (1981) Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine 60:208–217Google Scholar
- 18.Miniter MF, Stollar BD, Agnello V (1979) Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus. Arthritis Rheum 22:959–968Google Scholar
- 19.Nebout T, Sobel LA, Lagrue G (1977) Intravenous methylprednisolone pulses in diffuse proliferative lupus nephritis (letter). Lancet 1:909Google Scholar
- 20.Singsen BH, Bernstein BH, King KK, Hanson V (1976) Systemic lupus erythematosus in childhood: correlations between changes in disease activity and serum complement levels. J Pediatr 89:358–365Google Scholar
- 21.Urman JD, Rothfield NF (1977) Corticosteroid treatment in systemic lupus erythematosus. JAMA 238:2272–2276Google Scholar